IP Library Granted Patent US 6,919,176
Granted Patent B2
US 6,919,176 · App. 09/850,948 · Granted Jul 19, 2005

Polypeptides and nucleic acids associated with cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,919,176
App. No.
09/850,948
Granted
Jul 19, 2005
Kind
B2
Abstract

The present invention provides methods, reagents, and kits for diagnosing and treating cancer in a mammal, e.g., a human. This invention is based upon the discovery that G2A, GPR4, GPR65, and OGR1 are overexpressed and/or amplified in cancer. Methods to detect cancer or a propensity to develop cancer, to monitor the efficacy of a cancer treatment, and to treat cancer, by inhibiting the expression and/or activity of G2A, GPR4, GPR65, and OGR1 in a cancer cell are included.

Claims (14)

1. A method of detecting cancer, the method comprising steps of:

(i) providing a human tissue sample that is suspected of being cancerous, and

(ii) detecting an increase in the amount, relative to a control level, of a nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:8 in the tissue sample, thereby detecting the presence of cancer.

2. The method of claim 1 , wherein the detecting step comprising detecting the mRNA that encodes the polypeptide of SEQ ID NO:8.

3. The method of claim 2 , wherein the mRNA is detected using an amplification reaction.

4. The method of claim 1 , wherein the cancer is an epithelial cancer.

5. The method of claim 4 , wherein the epithelial cancer is selected from the group consisting of breast cancer, ovarian cancer, prostate cancer, colon cancer, and lung cancer.

6. The method of claim 1 , wherein the detecting step comprises detecting an increase in copy number of a gene that encodes the polypeptide, and wherein the cancer that is detected is breast cancer.

7. The method of claim 6 , wherein detecting an increase in copy number of the gene comprises a PCR amplification reaction.

8. The method of claim 5 , wherein the epithelial cancer is breast cancer.

9. The method of claim 5 , wherein the epithelial cancer is ovarian cancer.

10. The method of claim 5 , wherein the epithelial cancer is prostate cancer.

11. The method of claim 5 , wherein the epithelial cancer is colon cancer.

12. The method of claim 5 , wherein the epithelial cancer is lung cancer.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2005
From: AMGEN SF, LLC
To: AMGEN INC.
Reel/Frame 016871/0736 →
MERGER Recorded Jun 7, 2005
From: TULARIK INC.
To: ARROW ACQUISITION, LLC
Reel/Frame 016309/0003 →
CHANGE OF NAME Recorded Jun 7, 2005
From: ARROW ACQUISITION, LLC
To: AMGEN SF, LLC
Reel/Frame 016309/0812 →
MERGER Recorded Mar 18, 2005
From: TULARIK INC.
To: ARROW ACQUISITION, LLC
Reel/Frame 015796/0975 →
CERTIFICATE OF MEMBER Recorded Mar 18, 2005
From: AMGEN SF, LLC
To: AMGEN INC.
Reel/Frame 015796/0992 →
CHANGE OF NAME Recorded Mar 18, 2005
From: ARROW ACQUISITION, LLC
To: AMGEN SF, LLC
Reel/Frame 015798/0006 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2001
From: YANG, JIANXIN; AN, SONGZHU
To: TULARIK INC.
Reel/Frame 012268/0123 →